Rhythm Pharmaceuticals (RYTM) Common Equity (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Common Equity of $122.9 million for Q1 2026, up 548.68% year-over-year from $18.9 million in Q1 2025, and down 11.62% quarter-over-quarter from $139.1 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Common Equity (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Common Equity for 11 consecutive years, with $122.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 548.68% year-over-year to $122.9 million; the TTM figure through Mar 2026 stood at $122.9 million (up 548.68% YoY), while the FY2025 annual figure was $139.1 million, up 540.02% from the prior year.
- Common Equity declined to $122.9 million in Q1 2026 per RYTM's latest filing, from $139.1 million in the prior quarter.
- Across five years, Common Equity topped out at $281.2 million in Q3 2022 and bottomed at -$11.9 million in Q2 2025.
- Historically, Common Equity has averaged $135.2 million across 5 years, with a median of $148.8 million in 2025.
- On a YoY basis, Common Equity climbed as much as 1226.95% in 2025 and fell as far as 130.27% in 2025.
- Rhythm Pharmaceuticals' Common Equity stood at $264.3 million in 2022, then plunged by 35.76% to $169.8 million in 2023, then sank by 87.2% to $21.7 million in 2024, then surged by 540.02% to $139.1 million in 2025, then slipped by 11.62% to $122.9 million in 2026.
- Business Quant data shows RYTM's Common Equity at $122.9 million in Q1 2026, $139.1 million in Q4 2025, and $148.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 102.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.98 Mn |
| Mar 31, 2026 | 122.91 Mn |
| Dec 31, 2025 | 139.07 Mn |
| Sep 30, 2025 | 148.82 Mn |
| Jun 30, 2025 | -11.91 Mn |
| Mar 31, 2025 | 18.95 Mn |
| Dec 31, 2024 | 21.73 Mn |
| Sep 30, 2024 | 11.22 Mn |
| Jun 30, 2024 | 39.34 Mn |
| Mar 31, 2024 | 61.58 Mn |
| Dec 31, 2023 | 169.76 Mn |
| Sep 30, 2023 | 197.47 Mn |
| Jun 30, 2023 | 182.29 Mn |
| Mar 31, 2023 | 219.76 Mn |
| Dec 31, 2022 | 264.26 Mn |
| Sep 30, 2022 | 281.20 Mn |
| Jun 30, 2022 | 195.63 Mn |
| Mar 31, 2022 | 235.77 Mn |
| Dec 31, 2021 | 284.15 Mn |
| Sep 30, 2021 | 322.26 Mn |